Household & Personal Products · Founded 1993 · www.cupidlimited.com · BSE 530843 · NSE CUPID LTD · ISIN INE509F01029
No Notes Added Yet
Business
Cupid Ltd. is an India-based manufacturer and exporter of male and female condoms, water-based lubricants, and other related healthcare products. The company primarily operates on a Business-to-Business (B2B) and Business-to-Government (B2G) model, supplying its products to various government agencies, NGOs (Non-Governmental Organizations), and global aid organizations, particularly for public health initiatives in developing countries. It also has a smaller presence in the Business-to-Consumer (B2C) segment. Its core business model revolves around securing large international and domestic tenders for bulk supply of sexual wellness products.
Revenue Mix
Cupid Ltd.'s revenue is primarily derived from:
Male Condoms: Traditional rubber latex condoms.
Female Condoms: A significant and often higher-margin product segment, with Cupid being one of the few global manufacturers pre-qualified by organizations like UNFPA/WHO.
Lubricants: Water-based personal lubricants, often bundled with condom supplies or sold separately.
Other Healthcare Products: Includes items like hand sanitizers, antiseptic wipes, and potentially other medical devices, though these are typically smaller contributors.
While specific revenue percentages can fluctuate based on tender wins, female condoms often represent a substantial and strategic portion due to their niche market and higher average selling prices. The majority of revenue comes from exports to countries in Africa, Asia, and Latin America.
Industry
Cupid Ltd. operates in the global sexual wellness products industry, specifically within the condom and lubricant manufacturing sub-sectors. The industry is fragmented, with global giants (like Reckitt Benckiser - Durex, Lifestyles Healthcare) dominating the retail B2C market. Cupid's unique positioning lies in its strong focus and established track record in the B2B/B2G tender market, particularly for female condoms where it is one of the few WHO/UNFPA pre-qualified suppliers globally. This niche allows it to compete effectively against larger players who may not prioritize the tender segment or possess the necessary certifications for public health procurements. It holds a significant share in the global tender market for female condoms.
MOAT
Cupid's competitive advantages primarily stem from:
Regulatory Approvals & Prequalification: Its most significant moat is the rigorous international prequalification (e.g., WHO/UNFPA) required for supplying female condoms to global health organizations. This acts as a high barrier to entry due to stringent quality, manufacturing, and ethical standards, limiting direct competition in its core tender market.
Established Relationships & Track Record: Long-standing relationships and a proven track record with key international NGOs, government bodies, and aid agencies provide a significant advantage in securing recurring tenders.
Cost-Effective Manufacturing: Operating from India, the company benefits from relatively lower manufacturing costs, enabling competitive pricing for large-volume tenders.
Product Specialization: Its expertise and focus on female condoms, a technically challenging product, differentiate it from many general condom manufacturers.
Growth Drivers
Increasing Global Health Awareness: Rising awareness about sexual health, family planning, and STI/HIV prevention, particularly in developing nations, drives demand for condoms and lubricants.
Government & NGO Initiatives: Continued funding and procurement by international organizations (e.g., UNFPA, USAID) and national governments for public health programs remain a primary growth driver.
Geographic Expansion: Penetration into new export markets and securing tenders from new countries can boost volumes.
Product Diversification: Expansion into new related healthcare products or leveraging existing distribution channels for a broader product portfolio.
Increased Female Condom Adoption: Efforts by global health bodies to promote female condoms as an empowerment tool for women could lead to increased demand.
Risks
Dependency on Tenders: A significant portion of revenue relies on winning large, often cyclical, international and domestic tenders, leading to potential revenue volatility if major tenders are lost or delayed.
Intense Competition: While having a niche, the broader condom market is highly competitive, and even in tenders, there can be price pressure.
Regulatory & Approval Risks: Maintaining global certifications and complying with evolving international quality standards is critical and resource-intensive.
Raw Material Price Volatility: Fluctuations in the prices of raw materials (e.g., natural rubber latex) can impact manufacturing costs and margins.
Currency Fluctuations: As a major exporter, the company is exposed to foreign exchange rate volatility, which can impact profitability.
Socio-Cultural Factors: Demand for sexual wellness products can be influenced by social stigma, cultural norms, and religious beliefs in various markets.
Management & Ownership
Cupid Ltd. is a publicly listed company in India. It is primarily promoted and managed by its founder, Mr. Om Prakash Garg, and his family, who hold a significant stake in the company. The management has guided the company through its growth as a key player in the international tender market for sexual wellness products. The company's ownership structure includes the promoter group and public shareholders.
Outlook
Cupid Ltd. holds a strong niche position in the global tender market for sexual wellness products, particularly female condoms, supported by its critical international certifications and established relationships. This provides a stable base and potential for growth driven by increasing global health awareness and continued funding for public health initiatives. However, the business faces inherent volatility due to its high dependency on winning large tenders, which can fluctuate in volume and frequency. Competition, raw material price fluctuations, and currency risks also present ongoing challenges. The company's ability to diversify its product portfolio, expand into new geographies, and potentially increase its B2C presence, while maintaining its strong B2B/B2G credentials, will be crucial for sustained, balanced growth amidst these operational realities.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 40 | 63 | 44 | 42 | 46 | 56 | 65 | 84 | 93 | 120 |
| Other Income | 1 | 3 | 0 | 6 | 4 | 5 | 0 | 6 | 11 | 12 |
| Total Income | 41 | 66 | 44 | 47 | 51 | 61 | 65 | 90 | 104 | 132 |
| Total Expenditure | 28 | 32 | 32 | 31 | 35 | 43 | 43 | 56 | 59 | 82 |
| Operating Profit | 13 | 34 | 12 | 16 | 16 | 18 | 21 | 34 | 45 | 50 |
| Interest | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 12 | 32 | 11 | 14 | 14 | 16 | 20 | 32 | 43 | 47 |
| Provision for Tax | 3 | 8 | 2 | 4 | 3 | 4 | 5 | 8 | 10 | 11 |
| Profit After Tax | 9 | 24 | 8 | 10 | 11 | 12 | 15 | 24 | 33 | 36 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 |
| Profit After Adjustments | 9 | 24 | 8 | 10 | 11 | 12 | 15 | 24 | 33 | 36 |
| Adjusted Earnings Per Share | 0 | 0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Net Sales | 172 | 184 | 362 |
| Other Income | 7 | 20 | 29 |
| Total Income | 178 | 203 | 391 |
| Total Expenditure | 121 | 142 | 240 |
| Operating Profit | 57 | 61 | 150 |
| Interest | 2 | 2 | 4 |
| Depreciation | 3 | 4 | 4 |
| Exceptional Income / Expenses | 0 | 0 | 0 |
| Profit Before Tax | 53 | 55 | 142 |
| Provision for Tax | 13 | 14 | 34 |
| Profit After Tax | 40 | 41 | 108 |
| Adjustments | 0 | 0 | 0 |
| Profit After Adjustments | 40 | 41 | 108 |
| Adjusted Earnings Per Share | 0 | 0.3 | 0.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 7% | 0% | 0% | 0% |
| Operating Profit CAGR | 7% | 0% | 0% | 0% |
| PAT CAGR | 2% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 521% | 282% | 127% | 48% |
| ROE Average | 18% | 19% | 19% | 19% |
| ROCE Average | 17% | 17% | 17% | 17% |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Shareholder's Funds | 301 | 342 |
| Minority's Interest | 0 | 0 |
| Borrowings | 0 | 0 |
| Other Non-Current Liabilities | 2 | 8 |
| Total Current Liabilities | 17 | 21 |
| Total Liabilities | 320 | 372 |
| Fixed Assets | 58 | 67 |
| Other Non-Current Assets | 12 | 23 |
| Total Current Assets | 250 | 282 |
| Total Assets | 320 | 372 |
| #(Fig in Cr.) | Mar 2024 | Mar 2025 |
|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 27 |
| Cash Flow from Operating Activities | 8 | -11 |
| Cash Flow from Investing Activities | -80 | 45 |
| Cash Flow from Financing Activities | 99 | -1 |
| Net Cash Inflow / Outflow | 27 | 32 |
| Closing Cash & Cash Equivalent | 27 | 59 |
| # | Mar 2024 | Mar 2025 |
|---|---|---|
| Earnings Per Share (Rs) | 0.03 | 0.3 |
| CEPS(Rs) | 0.03 | 0.34 |
| DPS(Rs) | 0 | 0 |
| Book NAV/Share(Rs) | 0.15 | 1.82 |
| Core EBITDA Margin(%) | 29.54 | 22.74 |
| EBIT Margin(%) | 31.68 | 31.01 |
| Pre Tax Margin(%) | 30.62 | 29.89 |
| PAT Margin (%) | 23.21 | 22.28 |
| Cash Profit Margin (%) | 24.91 | 24.72 |
| ROA(%) | 12.46 | 11.82 |
| ROE(%) | 19.51 | 18.25 |
| ROCE(%) | 17.36 | 17.04 |
| Receivable days | 101.99 | 114.37 |
| Inventory Days | 33.27 | 57.01 |
| Payable days | 0.52 | 6.27 |
| PER(x) | 818.33 | 41.59 |
| Price/Book(x) | 159.67 | 6.97 |
| Dividend Yield(%) | 0 | 0 |
| EV/Net Sales(x) | 189.76 | 8.96 |
| EV/Core EBITDA(x) | 568.48 | 26.79 |
| Net Sales Growth(%) | 0 | 6.88 |
| EBIT Growth(%) | 0 | 4.63 |
| PAT Growth(%) | 0 | 2.59 |
| EPS Growth(%) | 0 | 925.59 |
| Debt/Equity(x) | 0.06 | 0.05 |
| Current Ratio(x) | 14.68 | 13.3 |
| Quick Ratio(x) | 13.76 | 11.33 |
| Interest Cover(x) | 30.05 | 27.74 |
| Total Debt/Mcap(x) | 0 | 0.01 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.07 | 44.8 | 44.8 | 45.61 | 42.52 | 42.52 | 42.52 | 45.55 | 45.55 | 46.03 |
| FII | 0.45 | 5.2 | 5.97 | 3.33 | 3.14 | 1.63 | 0.95 | 2.58 | 1.48 | 1.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.11 | 0.11 | 0.31 | 0.27 | 0.17 |
| Public | 54.48 | 50 | 49.23 | 51.06 | 54.34 | 55.75 | 56.43 | 51.56 | 52.7 | 52.79 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.6 | 0.6 | 12.02 | 12.24 | 11.41 | 11.41 | 11.41 | 12.23 | 12.23 | 61.9 |
| FII | 0.01 | 0.07 | 1.6 | 0.89 | 0.84 | 0.44 | 0.25 | 0.69 | 0.4 | 1.35 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.08 | 0.07 | 0.23 |
| Public | 0.73 | 0.67 | 13.21 | 13.7 | 14.58 | 14.96 | 15.14 | 13.84 | 14.15 | 70.98 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.33 | 1.34 | 26.84 | 26.84 | 26.84 | 26.84 | 26.84 | 26.85 | 26.85 | 134.47 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +7% | — | — | — |
| Operating Profit CAGR | +7% | — | — | — |
| PAT CAGR | +2% | — | — | — |
| Share Price CAGR | +521% | +282% | +127% | +48% |
| ROE Average | +18% | +19% | +19% | +19% |
| ROCE Average | +17% | +17% | +17% | +17% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 45.07 | 44.8 | 44.8 | 45.61 | 42.52 | 42.52 | 42.52 | 45.55 | 45.55 | 46.03 |
| FII | 0.45 | 5.2 | 5.97 | 3.33 | 3.14 | 1.63 | 0.95 | 2.58 | 1.48 | 1.01 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.11 | 0.11 | 0.31 | 0.27 | 0.17 |
| Public | 54.93 | 55.2 | 55.2 | 54.39 | 57.48 | 57.48 | 57.48 | 54.45 | 54.45 | 53.97 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.6 | 0.6 | 12.02 | 12.24 | 11.41 | 11.41 | 11.41 | 12.23 | 12.23 | 61.9 |
| FII | 0.01 | 0.07 | 1.6 | 0.89 | 0.84 | 0.44 | 0.25 | 0.69 | 0.4 | 1.35 |
| DII | 0 | 0 | 0 | 0 | 0 | 0.03 | 0.03 | 0.08 | 0.07 | 0.23 |
| Public | 0.73 | 0.74 | 14.81 | 14.6 | 15.43 | 15.43 | 15.43 | 14.62 | 14.62 | 72.57 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1.33 | 1.34 | 26.84 | 26.84 | 26.84 | 26.84 | 26.84 | 26.85 | 26.85 | 134.47 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.